Search

Your search keyword '"Schad, Sara"' showing total 30 results

Search Constraints

Start Over You searched for: Author "Schad, Sara" Remove constraint Author: "Schad, Sara"
30 results on '"Schad, Sara"'

Search Results

2. T cell immunotherapies engage neutrophils to eliminate tumor antigen escape variants

3. Tim-4+ cavity-resident macrophages impair anti-tumor CD8+ T cell immunity

5. 878 T cell immunotherapies recruit and activate neutrophils to eliminate tumor antigen escape variants

8. 997 T cell immunotherapies trigger neutrophils to eliminates heterogenous tumors

10. Calreticulin mutant myeloproliferative neoplasms induce MHC-I skewing, which can be overcome by an optimized peptide cancer vaccine

11. Calreticulin mutant myeloproliferative neoplasms induce MHC-I skewing, which can be overcome by an optimized peptide cancer vaccine

12. Tumor-induced double positive T cells display distinct lineage commitment mechanisms and functions

13. 772 MHC-I skewing in mutant calreticulin-positive myeloproliferative neoplasms is countered by heteroclitic peptide cancer vaccination

14. 99 T cell immunotherapies trigger neutrophil activation to eliminate tumor antigen escape variants

15. MHC-I skewing in mutant calreticulin-positive myeloproliferative neoplasms is countered by heteroclitic peptide cancer vaccination

16. 524 Tim-4+ resident macrophages impair anti-tumor immunity in the serous body cavities By sequestering viable and cytotoxic CD8+ T cells expressing high levels of phosphatidylserine

17. 444 MHC-I skewing in mutant calreticulin-positive myeloproliferative neoplasms is countered by heteroclitic peptide cancer vaccination

18. 549 Characterizing double positive T cells in the tumor microenvironment: a tale of promiscuous cell fates

19. Heteroclitic peptide cancer vaccine counters MHC-I skewing in mutant calreticulin-positive myeloproliferative neoplasms

23. Targeting Phosphatidylserine Enhances the Anti-Tumor Response to Tumor-Directed Radiation Therapy in a Preclinical Model of Melanoma

24. Abstract B35: Class IIa HDAC inhibition promotes an antitumor macrophage phenotype that induces breast tumor regression and inhibits metastasis

26. 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two

27. Abstract 1651: Targeting phosphatidylserine in combination with adoptive T cell transfer eliminates advanced tumors without off-target toxicities in a melanoma preclinical model

29. 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two

Catalog

Books, media, physical & digital resources